NCT07479979 2026-03-18
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Not yet recruiting
Clinical Trials
8 trialsNCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT05422027 2024-06-17
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04891744 2021-05-18
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase 1/2 Unknown